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INTRODUCTION 54	
A key strategy of TB control programs in high-resource countries is identification of 55	
latent TB infection (LTBI) and preventive therapy to avert progression to TB disease 56	
(1). Currently only tuberculin skin tests (TSTs) and interferon-γ release assays 57	
(IGRAs) are used for LTBI screening (2). IGRAs are functional blood-based assays 58	
that detect interferon-γ produced by memory T cells after stimulation with 59	
mycobacterial antigens (2). Currently two IGRAs are available, the T-SPOT.TB and 60	
the more widely used QuantiFERON-TB Gold (QFT) assay (3).  61	
 62	
Globally, the number of hematopoietic stem cell transplant (HSCT) and solid organ 63	
transplant (SOT) recipients is rising steadily. Transplant recipients require long-term 64	
immunosuppression, and consequently have a much greater risk of developing TB 65	
disease than the general population (4). Furthermore, mortality associated with TB 66	
disease is higher (4-6). (4, 5)(6). 67	
 68	
Calcineurin inhibitors, including cyclosporin and tacrolimus, are the most commonly 69	
used immunosuppressive agents after transplantation (7). They reduce T cell 70	
activation, thereby inhibiting production of various cytokines, including interferon-γ 71	
and interleukin-2 (IL-2) (8). Both cytokines play crucial roles in human anti-72	
mycobacterial immune responses (9, 10). 73	
 74	
TB screening in patients receiving immunosuppressive medication is complex (4, 11-75	
13). Considerable evidence shows that the sensitivity of TSTs is reduced in 76	
immunocompromised individuals (2, 14). Previous studies investigating IGRAs in the 77	
transplant setting have reported conflicting results, some suggesting they are reliable, 78	
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others concluding that their performance is impaired (15-18). The key limitation of all 79	
previous clinical studies is that no gold standard for LTBI exists (2). Therefore, the 80	
interpretation of negative IGRA results in immunosuppressed patients is difficult, as it 81	
is currently impossible to distinguish true absence of TB infection from a false-82	
negative result caused by immunosuppression. 83	
 84	
This study aimed to determine the impact of calcineurin inhibitors on the performance 85	
of QFT assays using an ex vivo model. Additionally, we investigated their impact on 86	
recently identified biomarkers of TB infection, mycobacteria-specific IL-2, 87	
interferon-γ inducible protein 10 (IP-10), and tumor necrosis factor-α (TNF-α) 88	
responses (9, 10). 89	
 90	
 91	
METHODS 92	
Study population 93	
Adults-with-a-previous-positive-IGRA-result-or-recent-TB-exposure-were-recruited-94	
at-a-TB-clinic-after-written-informed-consent. Potential-participants-with-known-95	
immunodeficiency-or-receiving-immunosuppressive-medication-were-excluded. The 96	
study-was-approved-by-the-National-Research-Ethics-Service-Committee 97	
(13/SC/0043).  98	
 99	
Interferon-gamma release assays 100	
From-each-participant, three-sets-of-QuantiFERON-TB-Gold-in-Tube-assays 101	
(Cellestis/Qiagen, Carnegie, Australia) comprising-an-antigen-stimulated, a-positive 102	
(mitogen) control-and-a-negative-control-tube-were-obtained. No-reagents-were-103	
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added-to-the-first-set (‘standard assay’). In-the-second-set, cyclosporin (Sandimmun; 104	
Novartis, Camberley, UK) was-added-to-each-tube-to-a-final-concentration-of-200 105	
ng/mL, a-common-target-level-in-the-HSCT-setting (19). In-the-third-set, tacrolimus 106	
(Prograf; Astellas, Killorglin, Ireland) was-added-to-each-tube-to-a-final-107	
concentration-of 10 ng/mL, a-typical-target-level-in-the-SOT-setting (20). Drugs-108	
were-added-within 4 hours-of-phlebotomy, and-samples-were-immediately-109	
transferred-into-a 37°C incubator. After 24 hours, supernatants-were-harvested, as-110	
per-manufacturer’s-instructions, followed-by-cryopreservation. 111	
 112	
Cytokine measurements 113	
Cytokine-concentrations-in-supernatants-were-determined-with-ProcartaPlex xMAP 114	
assays (Affymetrix-eBioscience, Hatfield, UK) measuring-interferon-γ, IP-10, IL-2 115	
and-TNF-α-according-to-manufacturer’s-instruction. Their-broad-dynamic-range-116	
allows-accurate-measurement-of-the-high-interferon-γ-concentrations-that-often-117	
occur-in-QFT-assays, which-exceed-the-upper-limit-of-QFT-ELISAs (13). Assays 118	
were read with a-Luminex-100-Bioanalyzer-with-xPONENT™-software (Luminex-119	
Corporation, Austin, TX, U.S.). 120	
 121	
Interpretation of QFT results 122	
QFT-results-were-interpreted-according-to-the-latest-version-of-the-manufacturer’s 123	
package-insert (UK version). Briefly, a-positive-result-was-defined-as-a-background-124	
corrected-interferon-γ-response ≥0.35 IU/mL and-simultaneously ≥25% of-the-nil-125	
control-sample-interferon-γ-concentration. A-negative-result-was-defined-as-a-126	
response-below-this-threshold-in-the-presence-of-a-valid-positive-control (i.e. 127	
background-corrected-interferon-γ-concentration- ≥0.5 IU/mL). An-indeterminate-128	
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assay-result-was-defined-as-a-sample-set-in-which-the-negative-control-failed (i.e. 129	
interferon-γ-concentration >8.0 IU/mL), or-in-which-the-positive-control-failed 130	
(background-corrected-interferon-γ-concentration <0.5 IU/mL). 131	
 132	
Statistical analyses 133	
All-cytokines-were-analyzed-in-pg/mL, except-interferon-γ, which-was-measured-in-134	
pg/mL-and-then-converted-to-IU/mL-(the-units-used-in-QFT-assays)-for-analysis, as-135	
previously-described (21). Statistical-comparisons-were-done-in-Prism-(V6.0; 136	
GraphPad, La-Jolla, CA, U.S.)-using-Wilcoxon-matched-pairs-signed-rank-tests. 137	
 138	
 139	
RESULTS 140	
A total of 18 participants were recruited, of which 13 had positive QFT results. For 141	
the analyses of antigen-stimulated cytokine responses only data from these 13 142	
participants were included, while for the analyses of positive control responses, data 143	
from all 18 were included. 144	
 145	
Interferon-γ responses and categorical QFT results 146	
Both cyclosporin and tacrolimus caused considerable reductions in background-147	
corrected interferon-γ concentrations in the antigen-stimulated samples in all 148	
participants (Figure 1). Compared with the standard assay (3.84 IU/mL; IQR: 0.74–149	
10.9) the median interferon-γ concentrations were significantly lower in the 150	
cyclosporin- and tacrolimus-treated assay sets (0.0 IU/mL, IQR: -0.12–0.18; p<0.001 151	
and 0.02 IU/mL, IQR: -0.006–0.13; p<0.001, respectively) (Figure 2A). In the 152	
cyclosporin- and tacrolimus-treated positive control samples the median interferon-γ 153	
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concentrations were also significantly lower (5.1 IU/mL, IQR: 1.6–18.9 and 14.3 154	
IU/mL, IQR: 3.5–39.1, respectively) than in the standard assays (66.6 IU/mL; IQR: 155	
28.0–103.3), but still considerably above the cut-off classifying positive controls as 156	
failed (Figure 2B). 157	
 158	
Of the 13 participants with a positive QFT result in the standard assay, 10 converted 159	
to a negative result in the cyclosporin-treated set, and two to an indeterminate result; 160	
one (participant 4) continued to have a positive result despite a markedly reduced 161	
antigen-stimulated interferon-γ response (0.76 vs 6.59 IU/mL in the standard assay). 162	
In the tacrolimus-treated set, 10 individuals converted to a negative, and two to an 163	
indeterminate result; one (participant 1) remained positive, again with markedly 164	
reduced response (0.43 vs 13.1 IU/mL). 165	
 166	
IL-2, IP-10 and TNF-α responses 167	
Background-corrected IL-2 and IP-10 concentrations were significantly lower in the 168	
antigen-stimulated samples in the cyclosporin- and tacrolimus-treated assay sets than 169	
in the standard assay (Figure 2A). In contrast, there was no significant difference in 170	
background-corrected TNF-α concentrations. TNF-α responses in the positive control 171	
samples were also largely maintained, although statistically there was a significant 172	
reduction in concentrations in tacrolimus-treated samples (Figure 2B). 173	
 174	
 175	
DISCUSSION 176	
This-study-provides-robust-evidence-that-calcineurin-inhibitors-have-a-significant-177	
adverse-effect-on-the-performance-of-IGRAs. Our-results-suggest-that-the-majority-178	
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of-patients-with-LTBI-who-are-on-treatment-with-cyclosporin-or-tacrolimus-would-179	
have-false-negative-IGRA-results-when-screened-for-TB, for-example-in-the-180	
context-of-contact-screening-following-exposure-to-a-case-with-pulmonary-TB. 181	
Importantly, the-ex-vivo-model-used-in-this-study-cannot-capture-the-long-term-182	
impact-of-calcineurin-inhibitors-on-T-cells, which-may-be-even-more-pronounced.  183	
 184	
The marked impact of calcineurin inhibitors on IGRAs is consistent with their known 185	
mechanism of action. A key property of this drug class is inhibition of T cell 186	
activation and suppression of pro-inflammatory cytokines, including interferon-γ and 187	
IL-2, in T cells (8, 22, 23), the main source of interferon-γ in functional assays 188	
determining anti-mycobacterial immune responses, including QFT assays (2). The 189	
observed reduction in IP-10 responses is also predicted, since IP-10 production is 190	
primarily induced by interferon-γ (24). It is unlikely that those observations are due to 191	
cytoxicity, as previous data show that even at a 100-fold greater concentration than 192	
used in this study cyclosporin has no significant cytotoxic effects on T cells (25). 193	
 194	
In contrast, TB antigen-induced TNF-α responses were not suppressed by cyclosporin 195	
or tacrolimus. This suggests that calcineurin inhibitor have only limited effect on 196	
macrophages, the principal source of TNF-α in immune responses directed against 197	
mycobacteria, consistent with published data (26). Furthermore, this observation 198	
suggests that in patients receiving calcineurin inhibitors novel TB assays based on 199	
TNF-α responses, which are currently in development (9, 10), may prove more robust 200	
than IGRAs.    201	
 202	
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In conclusion, considering our results together with previous data showing that the 203	
performance of TSTs is also impaired in immunosuppressed patients, both currently 204	
used LTBI screening tests should be regarded as unreliable in patients receiving 205	
calcineurin inhibitors. Although a positive IGRA result remains useful in this patient 206	
population, a negative result provides no meaningful information regarding the TB 207	
infection status.   208	
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Figure 1. Background-corrected interferon-γ concentrations in antigen-stimulated 222	
(left) and positive control (right) samples in individual participants in the standard 223	
assay set compared with sets with added cyclosporin (upper panel; n=13) and 224	
tacrolimus (lower panel; n=13). Dotted lines indicate the cut-off for a positive test 225	
result in antigen-stimulated samples (0.35 IU/mL), and the cut-off for a valid positive 226	
control response (0.5 IU/mL). 227	
 228	
 229	
 230	
  231	
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Figure 2. Background-corrected interferon-γ, IL-2, IP-10 and TNF-α concentrations 232	
in (A) antigen-stimulated (n=13) and (B) positive control (n=18) samples in standard 233	
assay sets and sets with added cyclosporin and tacrolimus. Box plot with Tukey 234	
whiskers; horizontal lines depict the medians; p-values calculated with Wilcoxon 235	
matched pairs signed-rank tests. Negative values are due to background correction 236	
(see Methods section). 237	
 238	
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